Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2017 Jul 6;59(4):790–802. doi: 10.1080/10428194.2017.1344905

Figure 2.

Figure 2

Current PD-1/PD-L1 and CTLA4 check point inhibitors in AML and MDS

CTLA-4 indicates cytotoxic T- lymphocyte-associated-protein 4; MHC indicates major histocompatibility complex; PD-1/PD-L1/2, programmed cell-death protein 1 receptor/ligand; T-cell indicates cytotoxic T lymphocytes